SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Universal Health Services, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline – UHS

STEVENSON, Md., Dec. 28, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of purchasers of Universal Health Services, Inc. (NYSE: UHS ) (“Universal Health” or the “Company”) securities during the period between February 26, 2015 and December 7, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until February 21, 2017 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Universal Health securities during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Universal Health admitted patients based on its own financial considerations and not upon the medical necessity of the patient and would keep patients admitted until their insurance payments ran out in order to ensure the maximum payment for its services, Universal Health’s revenues from inpatient care relied on unsustainable practices, and the Company lacked effective internal control concerning its practices and policies of admitting patients.

According to the complaint, following a December 7, 2016 investigative story on Universal Health regarding its practices, the value of Universal Health shares declined significantly.

If you have suffered a loss in excess of $100,000 from investment in Universal Health securities purchased on or after February 26, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html .  You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.

CONTACT:  Charles J. Piven Brower Piven, A Professional Corporation 1925 Old Valley Road Stevenson, Maryland 21153 Telephone: 410-415-6616 hoffman@browerpiven.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 7

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 5

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 8

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 11

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 11

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 7

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 12

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 11

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 12

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading

Top 5 Most Recently Viewed Articles

Understanding ADHD and the Role of RELEXXII in Treatment

Updated Category News Views 215

Supporting ADHD Awareness: The Role of RELEXXII This month marks a significant time for acknowledging and educating people about Attention Deficit Hyperactivity Disorder (ADHD). Alora Pharmaceuticals, the leading manufacturer behind RELEXXII® (methylphenidate hydrochloride extended-release tablet), is deeply committed to this cause. ADHD impacts various dimensions of...

Continue Reading
New Class Action Filed Against Paragon 28 Over Alleged Fraud

Updated Category News Views 111

Introduction to the New Class Action Against Paragon 28 Hagens Berman has recently taken action by filing a class action lawsuit against Paragon 28, Inc. (NYSE: FNA) alongside several of its senior executives. The case aims to hold the company accountable for alleged fraudulent activities affecting investors. Overview of the Allegations The lawsuit extends an ongoing...

Continue Reading
Subway Teams Up with ARC Raiders for Gaming Promo

Updated Category News Views 16

What’s Cooking Between Subway and Embark Studios? Subway’s diving headfirst into the gaming world, folks. It’s not a piece of cake to see a sandwich giant team up with a game studio, but today, Subway’s sidestepping the typical food deal. Instead, it's sharpening its digital claws with Embark Studios, a Stockholm-based game developer. They’re gearing up for the...

Continue Reading
CagriSema Breakthrough: Weight Loss Success in Adults

Updated Category News Views 312

Significant Weight Loss Achieved with CagriSema in Clinical Trial In recent findings, Novo Nordisk has unveiled compelling results from the extensive REDEFINE 1 trial, focusing on the innovative weight loss treatment, CagriSema. This clinical study assessed the efficacy of subcutaneous CagriSema—a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg—in...

Continue Reading
Endor Labs Achieves Remarkable Growth in Application Security

Updated Category News Views 390

Endor Labs Shows Impressive Revenue Growth Endor Labs, a leader in application security, proudly announces a significant milestone: a whopping 225% year-over-year revenue growth. This achievement highlights the increasing demand for robust security measures that can keep pace with the rapid transformations in software development, especially given the rise of AI...

Continue Reading